 Cell Line, Tumor
"Cell Line, Tumor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cell line derived from cultured tumor cells.
| Descriptor ID |
D045744
|
| MeSH Number(s) |
A11.251.210.190 A11.251.860.180
|
| Concept/Terms |
Cell Line, Tumor- Cell Line, Tumor
- Cell Lines, Tumor
- Line, Tumor Cell
- Lines, Tumor Cell
- Tumor Cell Lines
- Tumor Cell Line
|
Below are MeSH descriptors whose meaning is more general than "Cell Line, Tumor".
Below are MeSH descriptors whose meaning is more specific than "Cell Line, Tumor".
This graph shows the total number of publications written about "Cell Line, Tumor" by people in this website by year, and whether "Cell Line, Tumor" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 1 | 1 | | 2002 | 0 | 1 | 1 | | 2003 | 2 | 19 | 21 | | 2004 | 0 | 50 | 50 | | 2005 | 0 | 57 | 57 | | 2006 | 0 | 73 | 73 | | 2007 | 1 | 62 | 63 | | 2008 | 0 | 76 | 76 | | 2009 | 0 | 91 | 91 | | 2010 | 2 | 93 | 95 | | 2011 | 1 | 116 | 117 | | 2012 | 0 | 107 | 107 | | 2013 | 1 | 118 | 119 | | 2014 | 1 | 110 | 111 | | 2015 | 1 | 121 | 122 | | 2016 | 0 | 109 | 109 | | 2017 | 2 | 132 | 134 | | 2018 | 0 | 136 | 136 | | 2019 | 0 | 113 | 113 | | 2020 | 1 | 70 | 71 | | 2021 | 0 | 80 | 80 | | 2022 | 0 | 43 | 43 | | 2023 | 0 | 41 | 41 | | 2024 | 0 | 107 | 107 | | 2025 | 0 | 130 | 130 | | 2026 | 0 | 56 | 56 |
To return to the timeline, click here.
Below are the most recent publications written about "Cell Line, Tumor" by people in Profiles.
-
Keller AL, Dennis KA, Ohlstrom DJ, Parzych SE, Walker ZJ, Novak AJ, Pham-Danis C, Medha TN, Rahkola JT, Boorgula MP, Kohler ME, Sherbenou DW. Multiple Myeloma Cells Resistant to T-cell Therapies Exhibit a CD45+ Immunoevasive Phenotype. Cancer Immunol Res. 2026 Aug 04; 14(8):1307-1321.
-
Chang-Gu B, Baljinnyam T, Sowers ML, Dilawari R, Herring J, Sowers L. Targeting the NAD+ Salvage Pathway Blocks Metabolic Recovery and Enhances ß-Lapachone Toxicity in NQO1-Expressing Glioblastoma Cells. Cancer Res Commun. 2026 Aug 01; 6(8):1836-1849.
-
Contreras-Zárate MJ, Jaramillo-Gómez JA, Marquez-Ortiz RA, Pham TC, Koliavas SN, Ormond DR, Navarro AC, Nemenoff RA, Camidge DR, Cittelly DM. Targeting Wild-type NTRK in NTRK Fusion-Negative Lung Cancer Decreases Brain Metastases. Cancer Res Commun. 2026 Aug 01; 6(8):1850-1861.
-
Cole AR, Buj R, Uboveja A, Levasseur E, Tom A, Wang H, Kedziora KM, Chatoff A, Huacachino AA, Marcinkiewicz MM, Amalric A, Yang B, Tangudu NK, Noonan E, Danielson J, Naruse M, Elhaw AT, White S, Li D, Wallace CT, Keeney F, Lazure F, Elishaev E, Borho L, Townsend HA, Dowell RD, Clauset A, Jazwinska DE, Laird MS, Atiya H, Dangaj D, Coffman LG, Tseng G, Oesterreich S, Kossenkov A, Liu Q, Gomes AP, Gurkar AU, Schopfer FJ, Modugno F, Watkins SC, Zervantonakis IK, Bitler BG, Stallaert W, Hempel N, Snyder NW, Aird KM. The chemotherapy-induced senescence-associated secretome promotes cell detachment and metastatic dissemination through metabolic reprogramming. Nat Aging. 2026 Aug; 6(8):1647-1666.
-
Lin HK, Blake DA, Freeman R, Chen Y, Kim J, Johnson AM, Wells K, Mudigonda A, Liu W, Yadav P, Zeng F, Muhuri A, Min K, Sarkar S, Wang Y, Goyal S, Roberts RC, Christensen E, Ward AB, Heller B, Chun P, Dougan J, Porter CC, Barwick BG, Paulos CM, Yang L, Patgiri A, Thomas SN, Waller EK, Rafiq S. Modulating the VIP-VIPR pathway reprograms CAR T cells for superior antitumor efficacy in preclinical cancer models. Sci Transl Med. 2026 Jul 22; 18(859):eadt9565.
-
Lammers ML, Sholevar CJ, Karimzadeh M, Razmara AM, Cruz SM, Purl MC, Liu NM, Bakke D, Plagens RN, Elliott A, Sheng MK, Dongen CV, Tran T, Trinh AT, Nielsen RN, Kotamraju T, Farley LE, Iranpur KR, Mukarrama T, Gronchi A, Riedel RF, Monjazeb AM, Thorpe SW, Darrow MA, Kim J, Murphy WJ, Judge SJ, Canter RJ. Intratumoral TIGIT blockade augments antitumor responses and bypasses increased functionality of peripheral TIGIT+ NK cells in mouse and human models of bone and soft tissue sarcoma. J Immunother Cancer. 2026 Jul 22; 14(7).
-
Favours E, Tang H, Wong P, Ghilu S, Del Pozo V, Mironova E, Chen Y, Stearns T, Neuhauser S, Earley EJ, Erickson SW, Kwon JY, Jocoy EL, Groff D, Krytska K, Tsang M, Teicher BA, Mossé YP, Kolb EA, Hav M, Loo D, Houghton PJ, Bult CJ, Gorlick RG, Maris JM, Smith MA, Kurmasheva RT. Preclinical Activity of the B7-H3-Targeting Antibody-Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors. Clin Cancer Res. 2026 Jul 17; 32(14):3031-3042.
-
Pastrana CC, Nonavinkere Srivatsan S, Alberti MO, Hossan T, Ahmed T, Shao J, Chavez M, Grieb S, Padro JI, Paul DM, George DR, Patil A, Rai S, Graubert TA, Bailis JM, You Z, Walter MJ. Nonsense-Mediated RNA Decay Is a Targetable Vulnerability in Splicing Factor Mutant Myeloid Neoplasms by Enhancing R-Loop Accumulation and DNA Damage. Cancer Res. 2026 07 15; 86(14):3537-3553.
-
Padilla MS, Li JJ, Zhang Q, Patwari K, Shi S, Yamagata HM, Joseph RA, Hymms BN, Teerdhala SV, Fitzgerald E, Chalom OZ, Gupta K, Alameh MG, Weissman D, Le AD, Mitchell MJ. Lipid Nanoparticle Co-Delivery of mRNA and a Small Molecule Drug for Oral Cancer Chemoimmunotherapy. Adv Mater. 2026 Aug; 38(47):e73721.
-
Zeng Y, Xu J, Wang J, Xue L, Liu J, Geisler HC, Ma X, Melamed JR, Shi Q, Padilla MS, Luo Z, Zhu J, Thatte AS, Figueroa-Espada CG, Ang MJY, Murray AM, Yamagata HM, Kim D, Metzloff AE, Weissman D, Mitchell MJ. mRNA lipid nanoparticle cancer vaccine platform delivering multiple STING activators for enhanced antitumor activity. Proc Natl Acad Sci U S A. 2026 Jul 14; 123(28):e2525718123.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|